The strategic cooperation agreement signing ceremony between Pinshan Biotech (Shanghai) Co., Ltd. and Zhejiang YSK Biosciences Co., Ltd. was successfully held in Suzhou on April 23, 2025. Through equity investment, Pinshan Biotech has fully integrated the production capacity of YSK Bio's chromatography resin products. This cooperation breaks through traditional models, leveraging Pinshan Biotech's technological expertise in chromatography resins to achieve resource complementarity and strategic synergy. The partnership establishes a triple-engine growth model driven by R&D, production capacity, and market expansion. This milestone marks a crucial step forward in Pinshan Biotech's strategy to complete its integrated solutions across the entire bioprocess core membrane materials value chain.
Synergizing Strengths: Accelerating Chromatography Resin Industrialization
Mr. Han Han, Chairman and General Manager of Pinshan Biotech, and Mr. Ningning Ma, Chairman of YSK Bio, attended the signing ceremony alongside their core teams, joined by industry and media guests to witness this milestone event. The two parties engaged in in-depth discussions on "technology localization," "market deepening," and "supply chain indigenization," solidifying their collaborative vision.
Pinshan Biotech specializes in the R&D, production, and sales of core consumables for biotechnology and biopharmaceuticals. Guided by its mission to advance bioprocess optimization and foster industry integration, the company is committed to building a comprehensive bioprocess consumables portfolio spanning "cell culture + filtration + chromatography," contributing to global biomedical innovation. This strategic alliance with YSK Bio represents a powerful synergy of complementary strengths in technology development and manufacturing capabilities.
YSK Bio's agarose chromatography resin business, established in 2015, boasts nearly a decade of technological maturation and scaled production advantages. In March 2022, a state-of-the-art chromatography resin manufacturing facility was inaugurated in Zhuji City, featuring GMP-compliant Grade A production workshops, ISO13485/ISO9001/ISO14001 certifications, comprehensive DMF documentation, and RSF technical compliance. The facility comprises 3 production workshops, 3 laboratories, and multiple production lines capable of single-batch capacities up to 2,000L, with an annual production capacity of 200,000 liters.
Both teams recognize each other's industry leadership and have reached consensus on leveraging complementary strengths. Pinshan Biotech's specialized chromatography resin R&D center and mature process scale-up capabilities, combined with YSK Bio's manufacturing scale, will drive next-generation chromatography resin innovations. Through a three-dimensional collaboration model of "capital investment + resource integration + technological innovation," we aim to elevate core competitiveness and establish an industry benchmark. We firmly believe this partnership will significantly accelerate the localization of critical consumables, providing Chinese biopharmaceutical enterprises with superior, cost-effective solutions and propelling China's bio-industry toward new developmental heights.
Mr. Ningning Ma, Chairman of YSK Bio Stated:
After over a decade of R&D and development, YSK Bio's chromatography resin portfolio now spans five major categories encompassing nearly 100 products, including affinity chromatography, ion exchange chromatography, gel filtration chromatography, hydrophobic interaction chromatography, and mixed-mode chromatography. These products demonstrate performance comparable to imported alternatives while offering large production capacity, superior quality, and strong batch-to-batch consistency, fully addressing diverse customer requirements. We will deeply integrate our robust technological R&D capabilities with Pinshan Biotech's extensive sales network and acute market insights. Through this strategic synergy, we aim to accelerate commercial value realization and jointly resolve industry bottlenecks. We firmly believe this powerful alliance will deliver more diversified, premium-quality product options to the market, inject new vitality into sector development, and propel the entire industry toward unprecedented heights.
Chromatography Resin Production Site
Chromatography Resin Manufacturing Excellence: Empowering Bioprocess Industry Advancement
During the event, YSK Bio's chromatography resin products took center stage with comprehensive presentations highlighting their exceptional advantages.
Flexible Production Capacity
Single-batch capacity up to 2,000L; Annual production exceeding 200,000 liters; Agile response to full lifecycle needs from lab R&D to commercial manufacturing.
Rigorous Quality Control
Certified under ISO13485, ISO9001, and ISO14001 quality management systems; Comprehensive DMF documentation and RSF technical compliance; GMP-standard production management ensuring biopharmaceutical grade quality; Stable, controlled manufacturing processes with consistent product quality.
Secure Supply Chain
Fully controllable supply network with robust material management systems; High batch-to-batch consistency (RSD < 5%).
Regulatory Support
Complete production data archiving with ≥5-year traceability; Full clinical registration support for customers.
Comprehensive Product Portfolio
Five technology platforms covering affinity, ion exchange, gel filtration, hydrophobic interaction, and mixed-mode chromatography; Nearly 100 chromatography resin options.
For example: Protein A Captarose HL: An alkali-resistant, high-flow, high-capacity affinity resin for antibody purification. Featuring rigid crosslinked agarose matrix and alkali-tolerant recombinant Protein A ligand, it delivers superior flow rate and dynamic binding capacity. Ni Singarose FF/HP IMAC: Immobilized metal affinity chromatography (IMAC) resin with Ni²⁺ chelated to NTA-agarose gel, offering high binding capacity, excellent selectivity, easy regeneration, and cost-efficiency. Ideal for protein/peptide purification, particularly His-tagged proteins. This diverse product range meets varied bioprocess production requirements, driving industrial diversification and advancement.
In a standing ovation, representatives from both companies formally signed the strategic cooperation agreement. Moving forward, Pinshan Biotech and YSK Bio will jointly author a new chapter in the biopharmaceutical core consumables market. Committed to technological independence, market synergy, and ecological co-prosperity, the partnership aims to contribute significantly to high-quality development of China's bio-industry.
Pinshan Biotech specializes in the R&D, production, and sales of core consumables for biotechnology and biopharmaceuticals. Committed to advancing bioprocess optimization and vertical industry integration, the company supports global biomedical innovation and development through its extensive intellectual property portfolio and robust R&D capabilities. Pinshan Biotech's product portfolio spans critical biomanufacturing segments including cell culture, filtration, and chromatography, offering one-stop, customized solutions for biopharmaceutical clients worldwide.
About YSK Bio
Established in 2013, Zhejiang YSK Biosciences Co., Ltd. focuses on the development and production of premium serum-free media and protein/antibody purification resins. The company provides exceptional products and solutions for biopharmaceutical enterprises engaged in antibody, vaccine, and cell/gene therapy research. With comprehensive upstream and downstream product offerings and rigorous quality control systems, YSK Bio meets diverse client needs across therapeutic domains. Leveraging its forward-looking vision and high-quality product portfolio, YSK Bio has driven advancements in biopharmaceutical manufacturing. After over a decade of innovative R&D, the company maintains long-term partnerships with numerous domestic enterprises and research institutions.
